EZH2 and non-Hodgkin lymphoma: For example, a phase I study using the EZH2 chemical inhibitor GSK2816126 in elapsed/refractory diffuse large B-Cell lymphoma (DLBCL), other non-Hodgkin lymphomas (NHL), transformed follicular lymphoma (tFL), solid tumors, and multiple myeloma (MM) showed an evident anti-tumoral effect of the molecule [75].